Nucleix received a grant from the European Commission as part of the Horizon 2020 SME Instrument Phase I, under grant agreement number 696425. The grant was given to support the commercial development of lung cancer and colorectal cancer screening products that are based on Nucleix?s proprietary technology.
The European Commission?s Community Research and Development Information Service (CORDIS) has interviewed Nucleix about this project and featured the interview in their publication ? research*eu results magazine.
See the publication CORDIS EU RESEARCH Article